Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wyles

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
The Journal of Infectious Diseases|September 18, 2013
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b studyMark S Sulkowski, Minhee Kang, Roy Matining, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2024
Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trialWin Min Han, Sunil Solomon, Laura Smeaton, et al.
The Journal of Infectious Diseases|March 23, 2017
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirDavid Wyles, Michael Saag, Rolando M Viani, et al.
Journal of Gastroenterology|March 15, 2019
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infectionAtsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, et al.
Open Forum Infectious Diseases|April 21, 2021
T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral TherapyAnn W N Auma, Carey Shive, Sofi Damjanovska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
Antiviral Therapy|June 27, 2017
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvirDavid Wyles, Alessandra Mangia, Wendy Cheng, et al.
Open Forum Infectious Diseases|May 2, 2019
Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015Antoine Chaillon, Xiaoying Sun, Edward R Cachay, et al.
Journal of Hepatology|December 8, 2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvirDavid Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
The Journal of Infectious Diseases|September 18, 2013
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b studyMark S Sulkowski, Minhee Kang, Roy Matining, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2024
Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trialWin Min Han, Sunil Solomon, Laura Smeaton, et al.
The Journal of Infectious Diseases|March 23, 2017
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirDavid Wyles, Michael Saag, Rolando M Viani, et al.
Journal of Gastroenterology|March 15, 2019
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infectionAtsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, et al.
Open Forum Infectious Diseases|April 21, 2021
T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral TherapyAnn W N Auma, Carey Shive, Sofi Damjanovska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
Antiviral Therapy|June 27, 2017
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvirDavid Wyles, Alessandra Mangia, Wendy Cheng, et al.
Open Forum Infectious Diseases|May 2, 2019
Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015Antoine Chaillon, Xiaoying Sun, Edward R Cachay, et al.
Journal of Hepatology|December 8, 2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvirDavid Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Pageof 4